Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Locke, Frederick L., Miklos, David B., Jacobson, Caron A., Perales, Miguel-Angel, Kersten, Marie-José, Oluwole, Olalekan O., Ghobadi, Armin, Rapoport, Aaron P., McGuirk, Joseph, Pagel, John M., Muñoz, Javier, Farooq, Umar, van Meerten, Tom, Reagan, Patrick M., Sureda, Anna, Flinn, Ian W., Vandenberghe, Peter, Song, Kevin W., Dickinson, Michael, Minnema, Monique C., Riedell, Peter A., Leslie, Lori A., Chaganti, Sridhar, Yang, Yin, Filosto, Simone, Shah, Jina, Schupp, Marco, To, Christina, Cheng, Paul, Gordon, Leo I., Westin, Jason R.·2022·New England Journal of Medicine
DOI 10.1056/nejmoa2116133

Cited by (1,002)

Items 201–300 of 1,002

  1. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
    Frederick Lundry Locke, Olalekan O. Oluwole, John G. Kuruvilla, Catherine Thiéblemont, Franck Morschhauser, Gilles Salles, Steven P. Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto et al. · 2024 · Blood
  2. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells
    Gianluca Storci, Francesco De Felice, Francesca Ricci, Spartaco Santi, Daria Messelodi, Salvatore Nicola Bertuccio, Noemi Laprovitera, Michele Dicataldo, Lucrezia Rossini, Serena De Matteis et al. · 2024 · Journal of Clinical Investigation
  3. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
    Sanam Shahid, Susan E. Prockop, Georgia C. Flynn, Audrey Mauguen, Charlie White, Jennifer Bieler, Devin P. McAvoy, Kinga Hosszu, Maria Cancio, Ann Alice Jakubowski et al. · 2025 · Blood Advances
  4. Unity brings strength: Combination of CAR-T cell therapy and HSCT
    Ruihao Huang, Xiaoqi Wang, Xi Zhang · 2022 · Cancer Letters
  5. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Cost-Effectiveness Analysis
    Kelkar, Amar H., Cliff, Edward R. Scheffer, Jacobson, Caron A., Abel, Gregory A., Dijk, Stijntje W., Krijkamp, Eline M., Redd, Robert, Zurko, Joanna C., Hamadani, Mehdi, Hunink, M.G. Myriam et al. · 2023 · Annals of Internal Medicine
  6. Emerging roles of the gut microbiota in cancer immunotherapy
    Zhuangzhuang Shi, Hongwen Li, Wenting Song, Zhi‐Yuan Zhou, Zhaoming Li, Mingzhi Zhang · 2023 · Frontiers in Immunology
  7. Update on follicular lymphoma
    Jonathan W. Friedberg · 2023 · Hematological Oncology
  8. Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
    Hardik R. Mody, Ken Ogasawara, Xu Zhu, Dale Miles, Prathap Nagaraja Shastri, Jochem Gokemeijer, Michael Z. Liao, Sreeneeranj Kasichayanula, Tong‐Yuan Yang, Nagendra Venkata Chemuturi et al. · 2023 · Clinical Pharmacology & Therapeutics
  9. CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy
    Aurélien Guffroy, Léa Jacquel, Blandine Guffroy, Thierry Martin · 2024 · Joint Bone Spine
  10. Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics
    Felix Korell, Michael Olson, Diego Salas‐Benito, Mark B. Leick, Rebecca C. Larson, Amanda A. Bouffard, Harrison J. Silva, Alessandro Gasparetto, Trisha R. Berger, Michael C. Kann et al. · 2024 · Science Translational Medicine
  11. BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
    Ross Salvaris, Jamie Brennan, Katharine Louise Lewis · 2025 · Cancers
  12. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
    Eva M. González-Barca · 2022 · Frontiers in Immunology
  13. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments
    Skander Jemaa, Joseph Nathaniel Paulson, Martin Hutchings, Lale Kostakoglu, Judith Trotman, Samuel Tracy, Alex J. de Crespigny, Richard A.D. Carano, Tarec Christoffer El‐Galaly, Tina G. Nielsen et al. · 2022 · Cancer Imaging
  14. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation
    David J. Sermer, Pavania Elavalakanar, Jeremy S. Abramson, Maria Lia Palomba, Gilles Salles, Jon E. Arnason · 2022 · Blood Reviews
  15. Four challenges to CAR T cells breaking the glass ceiling
    Stefanie R. Bailey, Trisha R. Berger, Charlotte Graham, Rebecca C. Larson, Marcela Valderrama Maus · 2022 · European Journal of Immunology
  16. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
    Tingxun Lu, Jie Zhang, Zijun Yidan Xu-Monette, Ken H. Young · 2023 · Experimental Hematology and Oncology
  17. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
    William G. Breen, Jason R. Young, Matthew A. Hathcock, Roman O. Kowalchuk, Matthew P. Thorpe, Radhika Bansal, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose Caetano Villasboas et al. · 2023 · Blood Cancer Journal
  18. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study
    Trine Trab, Joachim Bæch, Lasse Hjort Jakobsen, Simon Husby, Marianne Tang Severinsen, Sandra Eloranta, Jette Sønderskov Gørløv, Judit Meszaros Jørgensen, Sif Gudbrandsdottir, Thomas Stauffer Larsen et al. · 2023 · The Lancet Haematology
  19. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B‐cell lymphoma
    Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Matsumoto Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa et al. · 2023 · Cancer Science
  20. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases
    Xia Lyu, Latika Gupta, Eleni Tholouli, Hector Chinoy · 2023 · Rheumatology
  21. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
    Mark P. Hamilton, Erin M. Craig, Cesar Gentille Sanchez, Alain Antoine Mina, John S. Tamaresis, Nadia Kirmani, Zachary J. Ehlinger, Shriya Syal, Zinaida Good, Brian J. Sworder et al. · 2024 · Blood Advances
  22. Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality
    Natalia M. Sutherland, Baijun Zhou, Lingxiao Zhang, Mei‐Sing Ong, Joseph Hong, Andrew Pak, Katherine J. Liu, Matthew J. Frigault, Marcela Valderrama Maus, Joshua A. Hill et al. · 2024 · Journal of Allergy and Clinical Immunology
  23. ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling
    Marina Gomez-Llobell, Carlos Serra Smith, Daniel Gómez Costas, Ignacio Alberto Gómez-Centurión, José Manuel García‐Domínguez, Vicente Escudero‐Vilaplana, Yolanda Fernández Bullido, Diego Carbonell, Marjorie Pion, Rebeca Bailén et al. · 2025 · Bone Marrow Transplantation
  24. CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
    Massimiliano Gambella, Simona Carlomagno, Anna Maria Raiola, Livia Giannoni, Chiara Ghiggi, Chiara Setti, Chiara Giordano, Silvia Luchetti, Alberto Serio, Alessandra Bo et al. · 2022 · Frontiers in Immunology
  25. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma
    Omran Saifi, William G. Breen, Scott C. Lester, William G. Rule, Bradley J. Stish, Allison Claire Rosenthal, Javier L Munoz, Yi Lin, Radhika Bansal, Matthew A. Hathcock et al. · 2022 · International Journal of Radiation Oncology*Biology*Physics
  26. Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: A systematic scoping review and narrative synthesis
    Gemma K. Reynolds, Beatrice Sim, Mary Ann Anderson, Tim D. Spelman, Benjamin W. Teh, Monica A. Slavin, Karin Thursky · 2023 · Clinical Microbiology and Infection
  27. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime
    Juan Pablo Alderuccio, Russ A. Kuker, Fei Yang, Craig H. Moskowitz · 2023 · Nature Reviews Clinical Oncology
  28. CAR‐T cell therapy for patients with hematological malignancies. A systematic review
    Daniel Maringelli Pasqui, Carolina de Oliveira Cruz Latorraca, Rafael Leite Pacheco, Rachel Riera · 2022 · European Journal Of Haematology
  29. Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosis
    Weicheng Ren, Hui Wan, Sulaf Abd Own, Mattias Berglund, Xianhuo Wang, Ming‐Yu Yang, Xiaobo Li, Dongbing Liu, Xiaofei Ye, Kristina Sonnevi et al. · 2023 · Leukemia
  30. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
    Samuel Vic, Jean‐Baptiste Thibert, Emmanuel Bachy, Guillaume Cartron, Thomas Gastinne, Franck Morschhauser, Fabien Le Bras, Kamal Bouabdallah, Fabien Despas, Jacques‐Olivier Bay et al. · 2024 · Blood Advances
  31. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years
    Philipp Berning, Mathilde Fekom, Maud Ngoya, Anthony H. Goldstone, Peter Dreger, Silvia Montoto, Hervé Finel, Evgenii Shumilov, Patrice Chevallier, Didier Blaise et al. · 2024 · Blood Cancer Journal
  32. Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
    Sophia Stock, Veit Bücklein, Viktoria Blumenberg, Giulia Magno, Alica‐Joana Emhardt, Alessandra M. E. Holzem, David M. Cordas dos Santos, Christian Schmidt, Stefanie Grießhammer, Lisa Frölich et al. · 2025 · HemaSphere
  33. CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
    David J. Stahl, Philipp Gödel, Hyatt Balke‐Want, Rahil Gholamipoorfard, Paul Segbers, Luis Tetenborg, Mirjam Koker, Janina Dörr, Lisa Gregor, Daniel Bachurski et al. · 2025 · Cancer Cell
  34. Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
    Lihua Elizabeth Budde, Huilai Zhang, Won Seog Kim, Dai Maruyama, Eduardo Magalhães Rego, Lalita Norasetthada, Huangming Hong, Muhıt Özcan, Young‐Woo Jeon, Danielle Leão Cordeiro de Farias et al. · 2025 · Journal of Clinical Oncology
  35. The role of viruses in HIV-associated lymphomas
    Kathryn Anne Lurain, Ramya Ramaswami, Robert Yarchoan · 2022 · Seminars in Hematology
  36. Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
    Michele Clerico, Irene Dogliotti, Andrea Aroldi, Chiara Consoli, Luisa Giaccone, Benedetto Bruno, Federica Cavallo · 2022 · Journal of Clinical Medicine
  37. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment
    Zhifen Yang, Violena Pietrobon, Maggie L. Bobbin, Ofir Stefanson, Jin Yang, Angshumala Goswami, Bennett Alphson, Hana Choi, Khristina Magallanes, Qi Cai et al. · 2023 · Journal of Translational Medicine
  38. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
    Olaf Penack, Christophe Peczynski, Christian Koenecke, Emmanuelle Polge, Andrea Kühnl, Nathalie Fégueux, Michael Daskalakis, Nicolaus Kröger, Peter Dreger, Caroline Besley et al. · 2023 · Journal for ImmunoTherapy of Cancer
  39. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma
    Qiqi Zhang, Cheng Zu, Ruirui Jing, Youqin Feng, Yanlei Zhang, Mingming Zhang, Yuqi Lv, Jiazhen Cui, Linhui Zhou, Ye Meng et al. · 2023 · Frontiers in Immunology
  40. Enabling CAR T ‐cell therapies for HIV ‐positive lymphoma patients – A call for action
    Tessa Hattenhauer, Rebekka Mispelbaum, Marcus Hentrich, Christoph Boesecke, Malte B. Monin · 2023 · HIV Medicine
  41. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy
    Vatsala Katiyar, J. Chesney, G. Kloecker · 2023 · Cancers
  42. Leukapheresis for CAR-T cell production and therapy
    Ilias Pessach, Arnon Nagler · 2023 · Transfusion and Apheresis Science
  43. Nanomaterials Boost CAR‐T Therapy for Solid Tumors
    Jun Long, Yian Wang, Xianjie Jiang, Junshang Ge, Mingfen Chen, Boshu Zheng, Rong Wang, Meifeng Wang, Meifang Xu, Ke Qi et al. · 2024 · Advanced Healthcare Materials
  44. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?
    Peng-Fei Zhang, Dan Xie · 2024 · Frontiers in Immunology
  45. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review
    Kednapa Thavorn, Emily Rose Thompson, Srishti Kumar, Aliisa Heiskanen, Anubhav Agarwal, Harold L. Atkins, Risa Shorr, Terry Hawrysh, Kelvin Chan, Justin Presseau et al. · 2024 · Value in Health
  46. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
    Frederick Lundry Locke, Tanya Siddiqi, Caron Alyce Jacobson, Armin Ghobadi, Sairah Ahmed, David Bernard Miklos, Miguel‐Angel Perales, Javier L Munoz, Warren Benjamin Fingrut, Martina Pennisi et al. · 2024 · Blood
  47. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention
    Fateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, Timothy S. Fenske, Faiqa Farrukh, Walter Longo, Othman Salim Akhtar, Anita D’Souza, Marcelo C. Pasquini, Guru Subramanian Guru Murthy et al. · 2024 · Blood Advances
  48. Overview of infectious complications among CAR T- cell therapy recipients
    Swarn Arya, Zainab Shahid · 2024 · Frontiers in Oncology
  49. Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
    Fatemeh Nasiri, Pouya Safarzadeh Kozani, Faeze Salem, Maral Mahboubi Kancha, Setareh Dashti Shokoohi, Pooria Safarzadeh Kozani · 2025 · Cancer Cell International
  50. Organoids as models of immune-organ interaction
    Marius F. Harter, Timothy Recaldin, Nikolche Gjorevski · 2025 · Cell Reports
  51. All roads lead to targeted diffuse large B-cell lymphoma approaches
    Pengpeng Xu, Yujia Huo, Weili Zhao · 2022 · Cancer Cell
  52. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights
    Alaa Mohammed Ali, Andre Henri Goy, Kieron M. Dunleavy · 2022 · Blood
  53. A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
    Omar Hameed Butt, Alice Yao Zhou, Beau M. Ances, John F. DiPersio, Armin Ghobadi · 2023 · Frontiers in Neurology
  54. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
    Dae Hyun Lee, Abhishek Kumar, Turab Jawaid Mohammed, Lauren Cole Peres, Melissa Alsina, Christina A. Bachmeier, Brandon Jamaal Blue, Jason B. Brayer, Sanjay Amrith Chandrasekhar, Ariel Felipe Grajales-Cruz et al. · 2023 · Blood Advances
  55. Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
    Sravya Tumuluru, James K. Godfrey, Alan B Cooper, Jovian Yu, Xiufen Chen, Brendan W. MacNabb, Girish Venkataraman, Yuanyuan Zha, Benedikt W. Pelzer, Joo Young Song et al. · 2025 · Blood
  56. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Xavier Deschênes‐Simard, Maria Bromberg, Sean M. Devlin, Mithat Gönen, Ofrat Beyar‐Katz, Andrew Ip, Ronit Marcus, Abraham Avigdor, Annamaria Ballweg, Emma Rabinovich et al. · 2025 · Blood Advances
  57. Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling
    Tereza Andreou, Constantina Neophytou, Maria Kalli, Fotios Mpekris, Triantafyllos Stylianopoulos · 2025 · Frontiers in Immunology
  58. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
    Fateeha Furqan, Mehdi Hamadani · 2022 · Therapeutic Advances in Hematology
  59. Bispecific CAR T-cells for B-cell Malignancies
    Fateeha Furqan, Nirav Niranjan Shah · 2022 · Expert Opinion on Biological Therapy
  60. CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions
    Claudio Jommi, Stéfania Bramanti, Marcello Pani, Alessandro Ghirardini, Armando Santoro · 2022 · Frontiers in Pharmacology
  61. Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
    Stijn De Munter, Juliane L. Buhl, Laurenz De Cock, Alexander Van Parys, Willem Daneels, Eva Pascal, Lucas Deseins, Joline Ingels, Glenn Goetgeluk, Hanne Jansen et al. · 2024 · Cancer Immunology Research
  62. A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
    Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stéfania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria Chiara Tisi, Matteo Giovanni Carrabba, Ilaria Cutini et al. · 2024 · Blood Cancer Discovery
  63. Stem-like CD8+ T cells in cancer
    Chelsea Steiner, Nathan Denlinger, Xiaopei Huang, Yiping Yang · 2024 · Frontiers in Immunology
  64. Sinonasal lymphoma: A primer for otolaryngologists
    Benjamin F. Bitner, Nyein Nyein Htun, Beverly Y. Wang, Elizabeth A. Brem, Edward C. Kuan · 2022 · Laryngoscope Investigative Otolaryngology
  65. FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
    Poornima Sharma, Yvette L. Kasamon, Xue Lin, Zhenzhen Xu, Marc Robert Theoret, Tejashri Purohit-Sheth · 2023 · Clinical Cancer Research
  66. Ocular surface toxicities associated with modern anticancer therapies
    R. C. Boucher, Oscar L. Haigh, Emmanuel Barreau, Stéphane Champiat, Olivier Lambotte, Clovis Adam, Marc Labétoulle, Antoine Rousseau · 2023 · Survey of Ophthalmology
  67. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
    Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason T. Romancik, Tamara Kay Moyo, Vaishalee Padgaonkar Kenkre, Thomas A. Ollila, Lindsey A. Fitzgerald, Brian T. Hess et al. · 2024 · Blood Advances
  68. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
    Samuel Yamshon, Caitlin K. Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle R. Demetres, Michelle S Pasciolla, John Paul Leonard, Tsiporah B. Shore, Peter Martin · 2024 · Clinical Lymphoma Myeloma & Leukemia
  69. Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations
    Katie S. Gatwood, Zahra Mahmoudjafari, Brittney Baer, Stacy Pak, Brian Lee, Hoim Kim, Karin M Abernathy, Bhagirathbhai Dholaria, Olalekan O. Oluwole · 2024 · Clinical Hematology International
  70. Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
    Francesco D’Alò, Silvia Bellesi, Elena Maiolo, Eleonora Alma, Flaminia Bellisario, Rosalia Malafronte, Marcello Viscovo, Fabrizia Campana, Stefan Hohaus · 2024 · Cancers
  71. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes
    Fareed Khawaja, Sairah Ahmed, Swaminathan P. Iyer, Joseph Sassine, Guy H. Handley, Rishab Prakash, Tracy VanWieren, Jennifer Jackson, Anna Zubovskaia, Jeremy Ramdial et al. · 2024 · Open Forum Infectious Diseases
  72. Disappearance of antiphospholipid antibodies after anti-CD19 chimeric antigen receptor T-cell therapy of B-cell lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome
    Eleonora Friedberg, Philipp Wohlfarth, Ana Iris Schiefer, Cathrin Skrabs, Winfried Franz Pickl, Nina Worel, Philipp Bernhard Staber, Ulrich Jaeger, Cihan Ay · 2024 · Journal of Thrombosis and Haemostasis
  73. Vaccination Therapy for Acute Myeloid Leukemia: Where Do We Stand?
    Kordelia Barbullushi, Nicolò Rampi, Fabio Serpenti, Mariarita Sciumé, Sonia Fabris, Pasquale De Roberto, Nicola Fracchiolla · 2022 · Cancers
  74. Early lymphocyte collection for anti‐CD19 CART production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma
    Tatyana Dubnikov Sharon, Miri Assayag, Batia Ronit Avni, Shlomit Kfir‐Erenfeld, Eyal Lebel, Moshe E. Gatt, Neta Goldschmidt, Polina Stepensky, Nathalie Asherie, Sigal Grisariu · 2023 · British Journal of Haematology
  75. Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
    Alejandro Martı́n, Almudena Cabero, Norma Carmen Gutierrez · 2023 · Journal of Clinical Medicine
  76. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
    Giulio Cassanello, Alejandro Luna, Lorenzo Falchi · 2024 · OncoImmunology
  77. Outcome after chimeric antigen receptor ( CAR ) T‐cell therapy failure in large B‐cell lymphomas
    Anna Dodero, Stéfania Bramanti, Martina Di Trani, Martina Pennisi, Silva Ljevar, Annalisa Chiappella, Massimo Magagnoli, Anna Guidetti, Francesco Corrado, Paulina Maria Nierychlewska et al. · 2023 · British Journal of Haematology
  78. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies
    Samer Al Hadidi, Helen Elisabeth Heslop, Malcolm K. Brenner, Masataka Suzuki · 2024 · Molecular Therapy
  79. Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies
    Wioletta Olejarz, Karol Artur Sadowski, Daniel Szulczyk, Grzegorz Władysław Basak · 2024 · International Journal of Molecular Sciences
  80. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
    Mengyang Di, Kunal C. Potnis, Jessica B. Long, Iris Isufi, Francine M. Foss, Stuart Seropian, Cary Philip Gross, Scott F. Huntington · 2024 · JNCI Cancer Spectrum
  81. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies
    Arun Kumar Arunachalam, Céline Grégoire, Beatriz Coutinho de Oliveira, Jan Joseph Melenhorst · 2024 · Blood Reviews
  82. Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma
    Bei Hu, Rakhee Vaidya, Ferdous Ahmed, Hamid Ehsan, Tamara Kay Moyo, Ryan W. Jacobs, Yifan Pang, Steven I. Park, Michelle L. Wallander, Vishal Shroff et al. · 2024 · Transplantation and Cellular Therapy
  83. Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma
    Fabian Ullrich, Paul Jan Bröckelmann, Amin T. Turki, Abdullah Khan, Elena-Diana Chiru, Marcus Hermann Friedrich Vetter, Bastian von Tresckow, Rainer Wirth, Raúl Córdoba, Valentín Ortiz‐Maldonado et al. · 2024 · Journal for ImmunoTherapy of Cancer
  84. Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy
    Shyam Ajay Patel, Jay Y. Spiegel, Saurabh Dahiya · 2024 · JAMA Oncology
  85. Emerging T-cell lymphomas after CAR T-cell therapy
    T. Braun, Florian Kuschel, K. Reiche, M. Merz, M. Herling · 2025 · Leukemia
  86. Allogeneic CART progress: platforms, current progress and limitations
    Ameneh Shokati, Maryam Sanjari-Pour, Mahshid Akhavan Rahnama, Saghar Hoseinzadeh, Mohammad Vaezi, Mohammad Ahmadvand · 2025 · Frontiers in Immunology
  87. Perspective: An International Fludarabine shortage: Supply Chain Issues Impacting Transplant and Immune Effector Cell Therapy Delivery.
    R. Maziarz, Amber H Diaz, D. Miklos, N. Shah · 2022 · Transplantation and Cellular Therapy
  88. Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
    Samuel Vic, Jean Lemoine, Philippe A. Armand, François Lemonnier, Roch Houot · 2022 · European Journal of Cancer
  89. The evolving therapy of DLBCL: Bispecific antibodies
    Martin Hutchings · 2023 · Hematological Oncology
  90. The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel ( ARI ‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma
    Núria Martínez‐Cibrián, Valentín Ortiz‐Maldonado, Marta Español‐Rego, Andrea Blázquez, Joan Cid, Miquel Lozano, Laura Magnano, Eva Giné, Juan Gonzalo Correa, Pablo Mozas et al. · 2023 · British Journal of Haematology
  91. Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort
    Corentin Le Cacheux, Audrey Couturier, Clara Sortais, Roch Houot, Morgane Péré, Thomas Gastinne, Amélie Seguin, Jean Reignier, Jean-Baptiste Lascarrou, Jean‐Marc Tadié et al. · 2024 · Annals of Intensive Care
  92. Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options
    Nicole Fabbri, Alberto Mussetti, Anna Maria Sureda · 2023 · Seminars in Hematology
  93. B cells mediate lung ischemia/reperfusion injury by recruiting classical monocytes via synergistic B cell receptor/TLR4 signaling
    Khashayar Farahnak, Yun Zhu Bai, Yuhei Yokoyama, Deniz B. Morkan, Zhiyi Liu, Junedh Amrute, Alejandro De Filippis Falcon, Yuriko Terada, Fuyi Liao, Wenjun Li et al. · 2024 · Journal of Clinical Investigation
  94. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
    Dobrin, Anton, Lindenbergh, Pieter L., Shi, Yuzhe, Perica, Karlo, Xie, Hongyao, Jain, Nayan, Chow, Andrew, Wolchok, Jedd D., Merghoub, Taha, Sadelain, Michel et al. · 2024 · Nature Cancer
  95. Optimization of older adults by a geriatric assessment–guided multidisciplinary clinic before CAR T-cell therapy
    Samuel J. Yates, John Cursio, Andrew S. Artz, Keriann Kordas, Michael Russell Bishop, Benjamin Avi Derman, Satyajit Kosuri, Peter A. Riedell, Justin Paul Kline, Andrzej J. Jakubowiak et al. · 2024 · Blood Advances
  96. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy
    Scott Ryan Goldsmith, Geoffrey Shouse, Florence Lennie Wong, Alysia Bosworth, Aleksi Iukuridze, Sitong Chen, June‐Wha Rhee, Matthew Genyeh Mei, Myo Htut, Murali Janakiram et al. · 2024 · Transplantation and Cellular Therapy
  97. Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
    Minoo Battiwalla, Michael Timothy Tees, Ian W. Flinn, Jeremy Mark Pantin, Jesús G. Berdeja, Tara K Gregory, Michael B. Maris, Vikas Bhushan, Estil A. Vance, John Mathews et al. · 2024 · Blood Advances
  98. The design of retroviral vectors used in the CAR‐T products, risk management, and future perspective
    Huifang Yin, Xuejing Wei · 2025 · MedComm
  99. Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
    Jae H. Park, Maria Lia Palomba, Karlo Perica, Sean M. Devlin, Gunjan L. Shah, Parastoo Bahrami Dahi, Richard Jirui Lin, Gilles Salles, Michael Scordo, Karthik Nath et al. · 2025 · Journal of Clinical Oncology
  100. Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
    Frederick William Vonberg, Imran Malik, Maeve A O'Reilly, Harpreet Hyare, Aisling S. Carr, Claire Roddie · 2025 · Journal of Neurology Neurosurgery & Psychiatry